id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-1285-0005,FDA,FDA-2021-N-1285,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Request for Comments,2022-03-10T05:00:00Z,2022,3,2022-03-10T05:00:00Z,2022-04-21T03:59:59Z,2022-04-22T01:00:34Z,2022-05022,0,0,0900006484fc26e6
FDA-2021-N-1285-0001,FDA,FDA-2021-N-1285,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Request for Comments,2021-12-13T05:00:00Z,2021,12,2021-12-13T05:00:00Z,2022-02-10T04:59:59Z,2022-02-10T02:00:38Z,2021-26891,0,0,0900006484ec07e5